Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91% Market Closed
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Egetis Therapeutics AB (publ)
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Egetis Therapeutics AB (publ)
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Egetis Therapeutics AB (publ)
STO:EGTX
Common Shares Outstanding
kr292.6m
CAGR 3-Years
18%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Common Shares Outstanding
kr101m
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Common Shares Outstanding
kr66.7m
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Common Shares Outstanding
kr135.4m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
3%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Common Shares Outstanding
kr343.4m
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
3%
BioArctic AB
STO:BIOA B
Common Shares Outstanding
kr88.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Egetis Therapeutics AB (publ)
Glance View

Market Cap
2.4B SEK
Industry
Biotechnology

Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

EGTX Intrinsic Value
9.63 SEK
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Egetis Therapeutics AB (publ)'s Common Shares Outstanding?
Common Shares Outstanding
292.6m SEK

Based on the financial report for Dec 31, 2023, Egetis Therapeutics AB (publ)'s Common Shares Outstanding amounts to 292.6m SEK.

What is Egetis Therapeutics AB (publ)'s Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
40%

Over the last year, the Common Shares Outstanding growth was 36%. The average annual Common Shares Outstanding growth rates for Egetis Therapeutics AB (publ) have been 18% over the past three years , 40% over the past five years .

Back to Top